ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,055.15
0.73%
US Tech 100
17,042.80
1.08%
다우존스 지수
38,170.56
0.71%
Bitcoin
59,030.56
1.36%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) 뉴스

SNDX Syndax Pharmaceuticals Inc

22.10
0.13 (0.59%)
최종 업데이트: 03:07:24
15분 지연
기업명 주식 심볼 시장 주식 타입
Syndax Pharmaceuticals Inc SNDX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.13 0.59% 22.10 03:07:24
개장가 저가 고가 종가 전일 종가
22.11 21.50 22.33 21.97
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
01/05/202420:00PRNUSSyndax to Announce First Quarter 2024 Financial Results and..
11/04/202405:05PRNUSSyndax Announces Participation at the Stifel 2024 Virtual..
08/04/202420:00PRNUSSyndax Presents Positive Pediatric Data from Pivotal..
06/04/202405:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
28/03/202420:00PRNUSSyndax Announces Completion of Enrollment in AUGMENT-101..
27/03/202405:05PRNUSSyndax Announces FDA Priority Review of NDA for Revumenib..
18/03/202420:00PRNUSSyndax Announces Appointment of Steven Closter as Chief..
02/03/202406:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
28/02/202407:28EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28/02/202407:21EDGAR2Form S-8 - Securities to be offered to employees in employee..
28/02/202406:05PRNUSSyndax Pharmaceuticals Reports Fourth Quarter and Full Year..
28/02/202406:03EDGAR2Form 8-K - Current report
26/02/202421:00PRNUSSyndax Announces Participation at Two Upcoming Investor..
21/02/202406:05PRNUSSyndax to Announce Fourth Quarter and Year-end 2023..
15/02/202402:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/02/202421:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202411:44EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
10/02/202406:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202406:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/02/202406:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
02/02/202406:10PRNUSSyndax Announces Participation at Two Upcoming Investor..
06/01/202406:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
03/01/202406:05PRNUSSyndax Announces Presentation at 42nd Annual J.P. Morgan..
02/01/202421:00PRNUSSyndax Highlights Recent Updates and Anticipated 2024..
20/12/202322:40EDGAR2Form 8-K - Current report
20/12/202306:16PRNUSSyndax Announces Closing of Public Offering of Common Stock..
16/12/202307:29EDGAR2Form 8-K - Current report
16/12/202307:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/12/202313:07PRNUSSyndax Announces Pricing of $200 Million Public Offering of..
15/12/202306:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/12/202306:00PRNUSSyndax Announces Proposed $150 Million Public Offering of..
13/12/202306:05EDGAR2Form 8-K - Current report
13/12/202302:00PRNUSSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial..
11/12/202321:30PRNUSSyndax Announces Positive Data for Revumenib in Patients..
11/12/202320:33BWIncyte und Syndax präsentieren bei ASH-Plenarsitzung weitere..
11/12/202307:00BWIncyte and Syndax Present Additional Data from Positive..
04/12/202321:00PRNUSSyndax to Host Investor Event to Discuss Axatilimab and..
02/12/202306:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
21/11/202323:00PRNUSSyndax Announces Data from Pivotal AUGMENT-101 Trial of..
07/11/202321:00PRNUSSyndax Announces Participation at Stifel Healthcare..
04/11/202305:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under..
03/11/202305:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202305:05PRNUSSyndax Pharmaceuticals Reports Third Quarter 2023 Financial..
03/11/202305:03EDGAR2Form 8-K - Current report
02/11/202322:00PRNUSSyndax Announces Results from the Pivotal AGAVE-201 Trial of..

최근 히스토리

NASDAQ
SNDX
Syndax Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유